Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07222345

Feasibility of High Intensity Interval Training in Survivors of Childhood, Adolescent, and Young Adult Hodgkin Lymphoma

This pilot study evaluates the feasibility of a 12-week high intensity interval training (HIIT) program in survivors of childhood, adolescent, and young adult Hodgkin lymphoma within 24 months of completing treatment. Preliminary efficacy of the HIIT intervention for improved cardiorespiratory fitness, body composition, physical function, autonomic response to exercise, peripheral neuropathy, biological aging markers, and physical activity will also be evaluated.

Primary Objective:

To determine the feasibility of a 12-week high intensity interval training (HIIT) program in survivors of childhood, adolescent, and young adult Hodgkin lymphoma within 24 months of completing treatment.

Feasibility will be assessed by:

* Participation Rate: Number of eligible survivors approached who enroll. * Completion Rate: Number of scheduled HIIT sessions attended and number of enrolled participants who complete post-intervention testing.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hodgkin Lymphoma Hemic and Lymphatic Diseases Hodgkin Disease Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type

Age range

10 year–25 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

St. Jude Children's Research Hospital

Memphis, Tennessee, 38105, United States

Location status: Recruiting

Location contact

Amy Berkman, MD

CONTACT

[email protected]

888-226-4343

About this study

Hodgkin lymphoma survivors face elevated risks of cardiovascular disease and premature aging. HIIT, which alternates high-intensity effort with recovery periods, has shown benefits in adult cancer survivors but has not been tested in younger populations. This study will assess whether recently treated survivors can complete a remotely supervised 12-week HIIT program and evaluate its effects on multiple health outcomes. Participants will undergo baseline and post-intervention assessments including exercise testing, body composition, autonomic function, and blood biomarkers. The intervention is delivered via a secure web-based platform with live supervision by exercise physiologists.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant has been diagnosed with Hodgkin lymphoma between the ages of 10 to 25 years.
  • Participant is between the ages of >10 and <25 years old the time of enrollment.
  • Participant has completed treatment (end of chemotherapy for those not receiving radiation therapy or end of radiation therapy) for Hodgkin lymphoma within 24 months prior to enrollment and recovered from any acute treatment-related adverse events.
  • Participant has been medically cleared to participate in physical activity.
  • Participant verbalizes understanding of directions for use of the web-based platform on the study provided iPad and heart rate monitor.

Exclusion criteria

  • Participant has evidence of relapsed disease.
  • Participant has a diagnosis of acute heart failure.
  • Participant reports currently participating in HIIT training or >420 minutes per week of moderate to vigorous physical activity.
  • Female participant who is currently pregnant.

Treatment and study plan

High Intensity Interval Training (HIIT)

Behavioral

Participants will complete a 12-week HIIT program with three 25-minute sessions per week. Each session includes warm-up, five cycles of high-intensity intervals (80-95% peak HR) and recovery periods (50-60% peak HR), and cool-down.

Primary outcomes

  1. Participation rate (percent of eligible participants approached who enroll)

    Time frame: Trial completion (12 weeks)

    Descriptive statistics will be reported

  2. Completion rate (percentage of scheduled HIIT sessions attended and percentage of post-intervention testing sessions completed)

    Time frame: Trial completion (12 weeks)

    Descriptive statistics will be reported

Other outcomes

  1. Cardiorespiratory fitness (VO2peak, ml/kg/min)

    Time frame: baseline at study entry, 12 weeks

    Descriptive statistics of the change between baseline and 12 weeks will be reported

  2. Ewing battery score of autonomic function (0 to 5 points)

    Time frame: baseline at study entry, 12 weeks

    Descriptive statistics of the change between baseline and 12 weeks will be reported

  3. Body mass index (weight and height will be combined to report body mass index in kg/m2)

    Time frame: baseline at study entry, 12 weeks

    Descriptive statistics of the change between baseline and 12 weeks will be reported

  4. Percent body fat (%)

    Time frame: baseline at study entry, 12 weeks

    Descriptive statistics of the change between baseline and 12 weeks will be reported

  5. Lean mass percentage (%)

    Time frame: baseline at study entry, 12 weeks

    Descriptive statistics of the change between baseline and 12 weeks will be reported

  6. Visceral fat level (score)

    Time frame: baseline at study entry, 12 weeks

    Descriptive statistics of the change between baseline and 12 weeks will be reported

  7. Hand grip strength (kg)

    Time frame: baseline at study entry, 12 weeks

    Descriptive statistics of the change between baseline and 12 weeks will be reported

  8. Knee extension strength (N/kg)

    Time frame: baseline at study entry, 12 weeks

    Descriptive statistics of the change between baseline and 12 weeks will be reported

  9. Modified total neuropathy scale (0 to 24 points)

    Time frame: baseline at study entry, 12 weeks

    Descriptive statistics of the change between baseline and 12 weeks will be reported

  10. DNA methylation

    Time frame: baseline at study entry, 12 weeks

    Descriptive statistics of the change between baseline and 12 weeks will be reported

  11. Mitochondrial DNA copy number

    Time frame: baseline at study entry, 12 weeks

    Descriptive statistics of the change between baseline and 12 weeks will be reported

  12. Telomere length (kb)

    Time frame: baseline at study entry, 12 weeks

    Descriptive statistics of the change between baseline and 12 weeks will be reported

  13. High-sensitivity C-reactive protein (mg/L)

    Time frame: baseline at study entry, 12 weeks

    Descriptive statistics of the change between baseline and 12 weeks will be reported

  14. Interleukin-6 (pg/mL)

    Time frame: baseline at study entry, 12 weeks

    Descriptive statistics of the change between baseline and 12 weeks will be reported

  15. Physical activity (kilocalories per week)

    Time frame: baseline at study entry, 12 weeks

    Descriptive statistics of the change between baseline and 12 weeks will be reported

Study contacts

Contact information is provided by the study sponsor or research team.

Amy Berkman, MD

CONTACT

[email protected]

888-226-4343

Sponsors and collaborators

Lead sponsor

St. Jude Children's Research Hospital

Other

Registry information

Important dates

Study start
2026
Primary completion
2028
Study completion
2029
First posted
Oct 29, 2025
Registry last updated
Jun 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.